Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts
September 26, 2024 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces dosing of the first subjects in the multiple-ascending dose (MAD)...
Kaida BioPharma Launches Social Media Channels
September 18, 2024 10:00 ET
|
Kaida Biopharma
Company dedicated to providing a new hope for patients with treatment-resistant gynecological cancers Lead program, KAD101 for the treatment of ovarian cancer rapidly advancing towards Phase 1...
Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors
September 18, 2024 08:30 ET
|
Sonnet BioTherapeutics Holdings, Inc.
SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’ Topline safety data of SB101 Phase 1 study expected by Q4 2024 PRINCETON, NJ, Sept. 18, 2024 (GLOBE...
Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor
July 18, 2024 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., July 18, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) today reported favorable safety and tolerability results from the...
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
April 09, 2024 16:35 ET
|
Prelude Therapeutics, Inc.
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9...
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
March 28, 2024 08:00 ET
|
Cocrystal Pharma, Inc.
FDA feedback following the Company’s submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza A clinical trial with oral CC-42344, a broad-spectrum...
QSAM Biosciences Receives Clearance from FDA to Expand Enrollment Criteria in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer
March 08, 2023 08:00 ET
|
QSAM Biosciences Inc.
Austin, TX, March 08, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
QSAM Biosciences Completes Enrollment of Initial Cohort in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer
February 28, 2023 08:00 ET
|
QSAM Biosciences Inc.
Austin, TX, Feb. 28, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
BioNTech beginnt Phase-1-Studie mit prophylaktischem Impfstoffkandidaten BNT163 gegen Herpes-Simplex-Virus-2
December 21, 2022 06:45 ET
|
BioNTech SE
Erste klinische Studie untersucht Sicherheit und Immunogenität des prophylaktischen Herpes-Virus-Impfstoffkandidaten BNT163 erstmalig am MenschenBNT163 ist der erste Kandidat aus BioNTechs...
BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163
December 21, 2022 06:45 ET
|
BioNTech SE
First-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163 BNT163 is the first candidate from BioNTech’s infectious disease mRNA vaccine...